Related Experiment Video
Updated: Jun 26, 2026

Intracranial Subarachnoidal Route of Infection for Investigating Roles of Streptococcus suis Biofilms in Meningitis in a Mouse Infection Model
Published on: July 1, 2018
Community-acquired bacterial meningitis in Southern Sweden 2013-2023: a population-based study of incidence,
Tobias West1,2, Robin Carlander3, Torgny Sunnerhagen3,4
1Division of Infection Medicine, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden. tobias.west@med.lu.se.
Purpose:
Despite advances in medical care, bacterial meningitis still poses a considerable health issue from a global perspective. An ageing population and increasing development and use of vaccines are likely to affect the incidence and aetiology. The aim of this study was to describe the incidence and aetiology of community-acquired bacterial meningitis (CABM) in our setting, as well as the serotypes of Streptococcus pneumoniae and Neisseria meningitidis causing CABM, in relation to available vaccines.
Method:
Patients of all ages with CABM in southern Sweden 2013-2023 were included. Patients were identified through records of cerebrospinal fluid tests from the Department of Clinical Microbiology, and through International Classification of Diseases 10 codes for bacterial meningitis. Age-standardised incidence rates were calculated based on the European Standard Population 2013.
Results:
During the study period, 244 episodes of CABM in 238 individuals were identified. Definitive aetiology could be established in 93% of episodes. Mean incidence rate was 1.63 per 100,000 person-years, with a trend of declining incidence during the study period. Streptococcus pneumoniae was the most common pathogen, accounting for 46.7% of episodes. 63.6% of the episodes of pneumococcal meningitis were caused by serotypes included in current vaccines.
Conclusion:
Pneumococcal meningitis is the primary driver of incidence and trends of all-cause community-acquired bacterial meningitis in southern Sweden. Further studies are warranted to investigate how vaccination could influence both disease incidence and shifts in serotype distribution, while also identifying optimal patient populations for targeted interventions.
Insights
Community-acquired bacterial meningitis (CABM) incidence is declining in southern Sweden, primarily driven by Streptococcus pneumoniae. Vaccination strategies are crucial for further reducing CABM and addressing serotype distribution.
Area of Science:
- Infectious Diseases
- Epidemiology
- Vaccinology
Background:
- Bacterial meningitis remains a global health concern, with incidence and causes influenced by demographics and vaccination.
- Understanding current trends in community-acquired bacterial meningitis (CABM) is essential for public health strategies.
Purpose of the Study:
- To determine the incidence and etiology of CABM in southern Sweden from 2013-2023.
- To analyze the serotypes of Streptococcus pneumoniae and Neisseria meningitidis causing CABM in relation to vaccine availability.
Main Methods:
- Retrospective study of all-age CABM patients in southern Sweden (2013-2023).
- Patient identification via cerebrospinal fluid test records and ICD-10 codes.
- Calculation of age-standardized incidence rates using the European Standard Population 2013.
Main Results:
- 244 CABM episodes identified; definitive etiology in 93%.
- Mean incidence rate of 1.63 per 100,000 person-years, showing a declining trend.
- Streptococcus pneumoniae was the most frequent pathogen (46.7%), with 63.6% of cases caused by vaccine-included serotypes.
Conclusions:
- Pneumococcal meningitis is the main driver of CABM incidence and trends in southern Sweden.
- Further research is needed on vaccination's impact on CABM incidence and serotype shifts.
- Identifying optimal patient groups for targeted interventions is crucial.
More Related Videos
Related Concept Videos
Investigation of Disease Outbreaks
Bacterial Meningitis
Mechanism of Antibiotic Resistance in MRSA
Viral Meningitis
Bacterial Meningitis I: Introduction
Bacterial Meningitis II: Pathophysiology

